• Hanx Biopharmaceuticals (Wuhan) entered a warrant placing deal dated Sept. 13, 2026 for up to 13,400,000 unlisted warrants.
• Warrants priced at HK$ 0.36 each; gross proceeds about HK$ 4.82 million, net proceeds about HK$ 3.86 million.
• Each warrant allows subscription for one new H share at an initial HK$ 36; exercise window runs 36 months from issue.
• Full exercise would raise up to HK$ 482.4 million gross; total net proceeds expected about HK$ 486.26 million.
• New shares would equal about 9.84% of existing issued share capital; placing targets at least seven independent investors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260913-12330367), on September 13, 2026, and is solely responsible for the information contained therein.